All In Biotech

Drug Trial Radar · NCT02106897

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jan 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Apr 30, 2014

Primary completion

May 24, 2016

Study completion May 24, 2016

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of Parts 1 and 2 is to evaluate the safety and tolerability of either single-ascending intravenous (IV) doses or a single subcutaneous (SC) dose of BIIB059 (litifilimab) in healthy volunteers (HV), and a single IV dose in participants with Systemic Lupus Erythematosus (SLE). The primary objective of Part 3 is to evaluate the safety and tolerability of multiple SC doses of BIIB059 in healthy volunteers and in participants with SLE. Secondary objectives of Parts 1 and 2 are as follows: To estimate the PK parameters of single-ascending IV doses of BIIB059 in healthy volunteers and a single IV dose of BIIB059 in participants with SLE; To estimate the PK parameters and bioavailability (F) of a single SC dose of BIIB059 in healthy volunteers; To evaluate the immunogenicity of BIIB059 administered to healthy volunteers and participants with SLE. Secondary objectives of Part 3 are as follows: To estimate the PK parameters of multiple SC doses of BIIB059 in healthy volunteers and in participants with SLE; To evaluate the immunogenicity of BIIB059 administered SC to healthy volunteers and participants with SLE.

Conditions

  • Systemic Lupus Erythematosus
  • Healthy Volunteers

Interventions

  • BIIB059 (litifilimab)Drug

    See Arm Descriptions

  • PlaceboDrug

    See Arm Descriptions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Week 32

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Orlando, Florida

  • Research Site

    Great Neck, New York

  • Research Site

    Duncansville, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.